Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Maxime Ramelet"'
Autor:
Olivier Duchamp, Gael Krysa, Loic Morgand, Hugo Quillery, Robin Artus, Maxime Ramelet, Jeremy Odillard, Peggy Provent, Sylvie Maubant, Caroline Mignard, Fabrice Viviani, Samira Benhamouche-Trouillet
Publikováno v:
Cancer Research. 82:1654-1654
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death and accounts for over 80% of primary liver cancer worldwide. Early stage HCC can be treated by local ablation, surgical resection or liver transplantation. Systemic ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bad312b075e21f4432042a8ddb4bddf1
https://doi.org/10.1158/1538-7445.am2022-1654
https://doi.org/10.1158/1538-7445.am2022-1654
Autor:
Sylvie Maubant, Marie Leblanc, Elisabeth Bertrand, Audrey Bertaux, Loic Morgand, Maxime Ramelet, Marie Lux, Olivier Duchamp, Fabrice Vivani
Publikováno v:
Cancer Research. 82:3053-3053
Preclinical and clinical studies have shed light on the beneficial role of bacteria for cancer therapy. Indeed, these studies have demonstrated that these microorganisms have beneficial properties that allow them to selectively colonize tumor and tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38c869161df2abe23eb2806d406c09da
https://doi.org/10.1158/1538-7445.am2022-3053
https://doi.org/10.1158/1538-7445.am2022-3053
Autor:
Peggy Provent, Laure Levenez, Hugo Quillery, Edwige Nicodeme, Maxime Ramelet, Samira Benhamouche-Trouillet, Loïc Morgand, Gael Krysa, Anne Lazzari, Robin Artus, Adelaide Ferment, Valerie Boullay, ‖ Anne-Bénédict Boullay, Olivier Duchamp, Jeremy Odillard
Publikováno v:
Cancer Research. 80:5638-5638
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death and accounts for >80% of primary liver cancer worldwide. Early stage HCC can be treated by local ablation, surgical resection or liver transplantation. Systemic pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ccfbe25e892f310be76ba7aa89cbf45
https://doi.org/10.1158/1538-7445.am2020-5638
https://doi.org/10.1158/1538-7445.am2020-5638
Publikováno v:
Cancer Research. 77:1681A-1681A
PD-1 targeting antibodies (nivolumab, pembrolizumab) are now approved in various tumor types either as second line treatment (locally advanced or metastatic urothelial carcinoma, advanced renal cell carcinoma, recurrent or metastatic head and neck sq
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::51ef351df0cf035769a2ff8ff701fba0
https://doi.org/10.1158/1538-7445.am2017-1681a
https://doi.org/10.1158/1538-7445.am2017-1681a